Eli Lilly has announced positive Phase 3 results showing that its BTK inhibitor Jaypirca (pirtobrutinib) significantly improved outcomes for patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) when combined with a fixed-duration venetoclax-based regimen. The findings add to growing evidence that targeted combination therapies may help patients achieve longer periods of disease control without continuous treatment.
The results come from the global BRUIN CLL-322 study, which evaluated Jaypirca in combination with venetoclax and rituximab versus venetoclax and rituximab alone in patients whose disease had returned or progressed after previous therapy. Investigators reported that the addition of Jaypirca reduced the risk of disease progression or death by 45%, meeting the trial’s primary endpoint of progression-free survival.
Notably, median progression-free survival had not yet been reached in the Jaypirca combination arm at the time of analysis, while patients receiving the standard regimen experienced a median progression-free survival of 39.7 months. These findings suggest that adding Jaypirca may provide a more durable treatment response for patients facing relapsed disease.
Researchers also observed additional clinical benefits from the triplet regimen. The combination improved time to next treatment and helped reduce tumor lysis syndrome risk in many patients, potentially simplifying management during venetoclax initiation. Safety findings were consistent with the known profiles of the individual medicines, and treatment discontinuation rates due to adverse events were comparable between study groups.
The BRUIN CLL-322 trial is particularly significant because it is among the first Phase 3 studies in relapsed CLL/SLL to demonstrate superiority over a modern venetoclax-containing control regimen. Most participants had previously received covalent BTK inhibitors, making the study highly relevant to current clinical practice.
Lilly plans to present the full dataset at scientific meetings and pursue discussions with global regulatory authorities. If approved for this indication, the regimen could offer physicians a new fixed-duration treatment strategy capable of delivering prolonged disease control while avoiding the need for indefinite therapy.
